Navigation Links
Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
Date:5/31/2011

n, abdominal pain, loss of appetite, vomiting, diarrhea, decreased hemoglobin, abnormal bleeding, nausea, fatigue and rash.

Gleevec is sometimes associated with stomach or intestinal irritation. Gleevec should be taken with food and a large glass of water to minimize this problem. There have been rare reports, including deaths, of stomach or intestinal perforation (a small hole or tear).

If you are experiencing any of the mentioned side effects, please be sure to speak with your doctor immediately.

Do not take any other medications without talking to your doctor or pharmacist first, including Tylenol® (acetaminophen); herbal products (St. John's wort, Hypericum perforatum); Coumadin® (warfarin sodium); rifampin; erythromycin; metoprolol; ketoconazole; and Dilantin® (phenytoin). Taking these with Gleevec may affect how they work, or affect how Gleevec works.  

You should also tell your doctor if you are taking or plan to take iron supplements.  Patients should also avoid grapefruit juice and other foods that may affect how Gleevec works.

About INC424INC424 is an oral inhibitor, of the JAK1 and JAK2 tyrosine kinases. INC424 is being investigated in primary myelofibrosis as well as post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF). INC424 is also being investigated in clinical trials for the treatment of polycythemia vera (PV).

Novartis licensed INC424 from Incyte for development and potential commercialization outside the US. Incyte has retained rights for the development and potential commercialization of INC424 in the US. Both the European Commission (EC) and the US Food and Drug Administration (FDA) have granted INC424 orphan drug status for myelofibrosis.

About TasignaTasigna® (nilotinib) 150 mg capsules is approved for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukem
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 The ambulance equipment ... decade due to the recession, an unstable ... advancements. This BCC Research report analyzes present ... the ambulance and emergency medical services equipment ... hemorrhage control devices, equipment used for burn ...
(Date:9/17/2014)... , Sept. 17, 2014  Dr. Stephen ... the White House today for National Recovery Month, stars ... consumer advocates released today. Consumer advocates were also joined ... who spoke out after losing her fiancée because of ... the doctor had a history of crack cocaine abuse. ...
(Date:9/17/2014)... 17, 2014 /PRNewswire-iReach/ -- ChemImage announced today ... improvements in the development of imaging technology ... normal and diseased tissue that minimizes the ... procedures, lowers surgical costs and potentially enhances ... The clinical and scientific teams ...
Breaking Medicine Technology:Ambulance and Emergency Equipment: Global Markets 2Ambulance and Emergency Equipment: Global Markets 3Ambulance and Emergency Equipment: Global Markets 4Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3Patient Outcomes Improve When Molecular Chemical Imaging Technology Is Used to Aid Robotic Surgical Procedures, According to New White Paper 2
... Calif., Dec. 5, 2011  Radient Pharmaceuticals Corporation  (OTCQX:RXPC) ... In Vitro Diagnostic (IVD) cancer test, announced ... the 2012 Gastrointestinal Cancers Symposium (ASCO Conference) were ... The meeting will be held on January 19-21, ...
... (NASDAQ and MTA: CTIC) announced today an update on ... application ("MAA") for Pixuvri. CTI is seeking a license ... relapsed or refractory aggressive non-Hodgkin,s lymphoma ("NHL") who have ... received the CHMP,s day 180 list of outstanding issues, ...
Cached Medicine Technology:Radient Pharmaceuticals' Two Abstracts Submitted to 2012 Gastrointestinal Cancers Symposium (ASCO) Regarding Onko-Sure® Utility in Colorectal Cancer Are Accepted for Presentation 2Radient Pharmaceuticals' Two Abstracts Submitted to 2012 Gastrointestinal Cancers Symposium (ASCO) Regarding Onko-Sure® Utility in Colorectal Cancer Are Accepted for Presentation 3European Medicines Agency's (EMA) Committee for Human Medicinal Products (CHMP)Tentatively Scheduled to Render an Opinion on PixuvriTM Marketing Authorization Application on January 19, 2012 2European Medicines Agency's (EMA) Committee for Human Medicinal Products (CHMP)Tentatively Scheduled to Render an Opinion on PixuvriTM Marketing Authorization Application on January 19, 2012 3European Medicines Agency's (EMA) Committee for Human Medicinal Products (CHMP)Tentatively Scheduled to Render an Opinion on PixuvriTM Marketing Authorization Application on January 19, 2012 4European Medicines Agency's (EMA) Committee for Human Medicinal Products (CHMP)Tentatively Scheduled to Render an Opinion on PixuvriTM Marketing Authorization Application on January 19, 2012 5
(Date:9/17/2014)... 2014 As kinship care continues to ... cannot live with their parents, emphasis on kinship care ... enhance services and supports for kinship caregivers and families. ... Kinship Care Conference is being held this week in ... practice, policy, program and service development for kinship caregivers, ...
(Date:9/17/2014)... reserved for the very healthy. Astronauts are selected ... and psychological standards to prepare them for any ... spaceflight, average people can now fly for enjoyment. ... information about what medical conditions or diseases should ... as most medical conditions have never been studied ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 People who struggle ... now head to http://www.perwickstrom.com and get the answer ... thing to point out, is that a business plan and ... they work together, commented Per Wickstrom. “The way I view ... by a business strategy which is part two.” , ...
(Date:9/17/2014)... Bioluminescence, nanoparticles, gene manipulation these sound like ... in fact, they are components of an exciting ... In preclinical animal models of metastatic prostate cancer, ... VCU Institute of Molecular Medicine and Johns Hopkins ... molecular imaging approach that could revolutionize doctors, ability ...
(Date:9/17/2014)... September 17, 2014 Catalent Pharma ... technologies and development solutions for drugs, biologics and ... OptiPact™, an integrated service and technology offer based ... provided from the company’s 450,000 sq. ft. Kansas ... ability to integrate optimal formulation, development, analytical expertise, ...
Breaking Medicine News(10 mins):Health News:Arizona’s Children Association Kinship Service Providers Invited to Present at the CWLA National Conference 2Health News:Space: The final frontier… open to the public 2Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:New OptiPact™ Technology Introduced by Catalent 2
... , PTs and PTAs listed as occupations that will "likely ... July 21 The nation,s aging population and expanded health care coverage ... Physical Therapy Association (APTA) as a new federal report (1) that presents ... next 5 to 10 years is released. , ...
... , MINNEAPOLIS and COLUMBUS, Ohio, ... MEDNETWorld.com (MEDNET), a leader in Nationwide Health ... with The Rubicon Group, eHealth Ohio, Bostech Corporation and ... (HPOC) Service enabling interoperable electronic exchange of clinical data ...
... 21 , , Rochester Medical Corporation ... on Thursday July 30, 2009. The Company will then hold a quarterly ... 3:30 p.m. central time (4:30 p.m. eastern time). , , ... at Rochester Medical,s website at www.rocm.com . To listen ...
... , ANDOVER, Mass., July 21 ... that serves the Texas Midwest area, finished its implementation of ... for advanced authentication. Following its enterprise roll-out of Sentillion,s ... Go to enable caregivers in its trauma center to use ...
... Texas, July 21 GVI Security Solutions, Inc. (OTC Bulletin ... featuring the complete Samsung Electronics line of products, announced that ... video surveillance solution for a North East pharmacy chain. , ... surveillance solution is based on GVI Samsung high performance/low light ...
... , , ... Advice Networks , the nation,s leading provider of physician ... state-of-the-art wireless broadband technology solution that delivers real-time health ... flat-screen monitors. Strategically located in the back office, medical ...
Cached Medicine News:Health News:President's Council Projects Growth For Physical Therapy Profession 2Health News:Partnership Collaborates on HIE for Interoperability of Electronic Health Records and Patient Data in Ohio 2Health News:Rochester Medical Announces Third Quarter 2009 Earnings Conference Call July 30, 2009 2Health News:Hendrick Health System Deploys Sentillion's Tap & Go Advanced Authentication Solution 2Health News:Hendrick Health System Deploys Sentillion's Tap & Go Advanced Authentication Solution 3Health News:GVI Security Solutions Samsung Video Surveillance Solution Selected by North East Pharmacy Chain 2Health News:Healthy Advice Networks Announces the Launch of PracticeWire; Technology to Deliver Real-time Healthcare Content to Physicians 2
The CGIL iridectomy contact glass was designed by Riquin, Fankhauser et al. to perform full thickness peripheral laser iridectomies....
The CGVL vitrectomy contact glass was designed by Rol, Fankhauser et al. for photodisruptive YAG laser procedures in the posterior vitreous....
For newly born children 10 mm internal diameter of the cornea part. Designed to work with argon/YAG Lasers....
... The HAAG-STREIT OM 900 Ophthalmometer uses ... the three requirements of Helmholtz: 1. The ... of the distance between the Ophthalmometer and ... are independent of the distance between the ...
Medicine Products: